Diagnostic delay is common in pediatric inflammatory bowel disease
The incidence of pediatric inflammatory bowel disease is rising in Canada and internationally; subtypes include Crohn disease, ulcerative colitis and unclassified. In a prospective study involving a tertiary centre cohort in Toronto, time to diagnosis was longer in cases of Crohn disease than in ulcerative colitis (6.8 v. 2.4 mo, respectively).1 For Crohn disease, diagnostic delay was associated with height impairment 1 year after presentation.1
Extraintestinal manifestations of pediatric inflammatory bowel disease can occur before diagnosis
Most patients will present with diarrhea (bloody in ulcerative colitis and nonbloody in Crohn disease) and pain. Extraintestinal manifestations occur in about 5%–10% of patients before diagnosis; arthritis and aphthous stomatitis are reported more frequently before diagnosis, and osteopenia is reported more frequently after diagnosis.2 The lifetime incidence of at least 1 extraintestinal manifestation is about 25%.2
The presence of perianal disease can be a highly specific finding when Crohn disease is suspected
About 15% of pediatric patients with newly diagnosed Crohn disease have perianal disease within 30 days of diagnosis, two-thirds with fistulas and abscesses.3
Once infection has been excluded, investigation of nonbloody diarrhea lasting longer than 2 weeks should be started in primary care4
About 80% of children with pediatric inflammatory bowel disease will have 1 or more of the following: anemia, raised erythrocyte sedimentation rate, raised C-reactive protein level, thrombocytosis and hypoalbuminemia.5 Tissue transglutaminase immunoglobulin A (IgA) and total serum IgA testing will aid investigation of celiac disease; serology will be normal in irritable bowel syndrome.
Fecal calprotectin testing can aid in the diagnosis, as high levels indicate intestinal mucosa inflammation
Calprotectin is a neutrophil protein biomarker found in stool. Once infection has been excluded, patients with diarrhea should have fecal calprotectin testing to help stratify for urgent or routine evaluation by a specialist.6 In one meta-analysis, raised fecal calprotectin levels (> 250 μg/g) had an overall sensitivity of 0.90 and specificity of 0.85 for diagnosing pediatric inflammatory bowel disease.6
Acknowledgement
The authors thank Dr. Sally Lawrence, pediatric gastroenterologist at BC Children’s Hospital, for assistance with the manuscript.
Footnotes
Competing interests: Neil Chanchlani reports grants from Crohn’s and Colitis UK. Richard Russell reports consultation fees, research grants or honoraria from Nestlé Health Science, AbbVie, Takeda, NAPP Pharmaceuticals, Mead Johnson, Nutricia, Janssen, Therakos, Celltrion and Vifor Pharma.
This article has been peer reviewed.
Disclaimer: Neil Chanchlani is an associate editor for CMAJ and was not involved in the editorial decision-making process for this article.
In this issue
Article tools
Jump to section
- Article
- Diagnostic delay is common in pediatric inflammatory bowel disease
- Extraintestinal manifestations of pediatric inflammatory bowel disease can occur before diagnosis
- The presence of perianal disease can be a highly specific finding when Crohn disease is suspected
- Once infection has been excluded, investigation of nonbloody diarrhea lasting longer than 2 weeks should be started in primary care4
- Fecal calprotectin testing can aid in the diagnosis, as high levels indicate intestinal mucosa inflammation
- Acknowledgement
- Footnotes
- References
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.